MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27009743.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0229 and PMC identifier 4911276.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
MET exon 14 alterations are a diverse group of mutations, many of which disrupt splice acceptor or donor sites leading to exon 14 skipping, impaired receptor degradation, and oncogenic transformation. These alterations are clinically targetable with MET-directed therapy. Clin Cancer Res; 22(12); 2832-4. ©2016 AACRSee related article by Tong et al., p. 3048.
Medical subject headings
- Alternative Splicing
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Proto-Oncogene Proteins c-met